Boehringer Ingelheim's Trajenta ranked no.1. among the outpatient prescription cost of DPP-4 family drugs
According to the outpatient prescription cost of DPP-4 family drugs in the first half of 2014 based on Ubist data, it was identified that Boehringer Ingelheim's Trajenta ranked no.1. Trajenta used sales capacity of Yuhan Corporation as a steppingstone and showed 13.5% growth from 22.1 billion won...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
